Medicare Enrolled
Dr. Richard Haddad, MD
Optician · Red Bank, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Haddad from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Haddad?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Haddad
Dr. Richard Haddad is an optician specialist in Red Bank, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Haddad performed 541,676 Medicare services across 3,160 unique beneficiaries.
Between the years covered by Open Payments, Dr. Haddad received a total of $1,184,634 from 84 pharmaceutical and/or device companies across 3812 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Haddad is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 0% volume in NJ
$1,184,634 industry payments
Medicare Practice Summary
Medicare Utilization ↗541,676
Medicare services
Top 0% in NJ for optician
3,160
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~27,084 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
313,200 | $4 | $12 |
| Tocilizumab injection (Actemra) | 104,040 | $5 | $10 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
45,100 | $10 | $30 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
31,875 | $33 | $75 |
| Romosozumab injection (Evenity) for osteoporosis | 18,480 | $8 | $12 |
| Belimumab injection, 10 mg An injection of belimumab, a medication administered at a dose of 10 mg. |
7,848 | $40 | $59 |
| Joint lubricant injection (TriVisc) An injection of hyaluronan or a derivative into a joint space. The dose specified is 1 milligram. |
5,975 | $7 | $25 |
| Denosumab injection (Prolia/Xgeva) | 5,760 | $18 | $27 |
| Betamethasone steroid injection An injection containing a combination of betamethasone acetate and betamethasone sodium phosphate. |
1,923 | $5 | $10 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
1,574 | $64 | $150 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
1,076 | $114 | $204 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
1,051 | $12 | $50 |
| Extended-release steroid injection (Zilretta) An injection of triamcinolone acetonide using a preservative-free, extended-release microsphere formulation. The dosage is measured in milligrams. |
992 | $13 | $25 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
807 | $68 | $127 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
450 | $58 | $115 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
349 | $95 | $153 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
258 | $42 | $101 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
223 | $1 | $5 |
| Ultrasound-guided large joint aspiration or injection This procedure uses ultrasound imaging to guide the removal of fluid from or the injection of medication into a large joint. |
152 | $93 | $201 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
110 | $6 | $52 |
| Fluoroscopic guidance for needle placement Use of real-time X-ray imaging to guide the precise placement of a needle during a medical procedure. |
94 | $103 | $150 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
53 | $79 | $170 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
50 | $129 | $230 |
| Ketorolac injection, per 15 mg An injection of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, administered in doses measured per 15 mg. |
36 | $0 | $3 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
32 | $25 | $100 |
| Joint fluid aspiration or injection, small joint Removal of fluid from a small joint or injection of medication into a small joint. |
28 | $40 | $76 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
28 | $128 | $225 |
| New patient office visit, complex (60-74 min) | 24 | $179 | $274 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
22 | $49 | $125 |
| Ultrasound-guided small joint aspiration or injection This procedure involves removing fluid from or injecting medication into a small joint while using ultrasound imaging to guide the needle placement. |
21 | $71 | $200 |
| Trigger point injection, 1-2 muscles A procedure involving the injection of medication into one or two specific muscles to treat trigger points. |
18 | $40 | $89 |
| SARS-CoV-2 immunoassay test A laboratory test using immunoassay techniques to detect the presence of severe acute respiratory syndrome coronavirus. |
14 | $35 | $200 |
| Ultrasound-guided joint aspiration or injection Removal of fluid from or injection into a medium-sized joint using ultrasound guidance to ensure accurate placement. |
13 | $68 | $200 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
14.4% high complexity
85.3% medium
0.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,184,634
Total received (2018-2024)
Avg $169,233/year across 7 years
Top 0% in NJ for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
84
Companies
3,812
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,137,924 (96.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$31,508 (2.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,202 (1.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$144,722
2023
$126,986
2022
$155,523
2021
$109,682
2020
$92,775
2019
$302,803
2018
$252,143
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$49,100
ABBVIE INC.
$46,199
GlaxoSmithKline, LLC.
$16,970
UCB, Inc.
$8,708
AstraZeneca Pharmaceuticals LP
$8,148
Amgen Inc.
$6,558
Lilly USA, LLC
$5,507
E.R. Squibb & Sons, L.L.C.
$1,379
Intra-Sana Laboratories
$437
Novartis Pharmaceuticals Corporation
$315
PFIZER INC.
$261
Phathom Pharmaceuticals, Inc.
$251
ANI Pharmaceuticals, Inc.
$158
GENZYME CORPORATION
$116
Mallinckrodt Hospital Products Inc.
$98
Genentech USA, Inc.
$77
Aurinia Pharma U.S., Inc.
$66
Pacira Pharmaceuticals Incorporated
$65
Alexion Pharmaceuticals, Inc.
$51
SCILEX PHARMACEUTICALS INC.
$49
IDORSIA PHARMACEUTICALS US INC
$48
Boehringer Ingelheim Pharmaceuticals, Inc.
$48
Organon Llc
$42
Nevro Corp.
$38
Sandoz Inc.
$18
Collegium Pharmaceutical, Inc.
$16
Top 3 companies account for 77.6% of 2024 payments
All-time payments by company (2018-2024) ›
Celgene Corporation
$183,115
Horizon Therapeutics plc
$122,975
ABBVIE INC.
$117,978
AbbVie, Inc.
$87,423
Janssen Biotech, Inc.
$86,888
Lilly USA, LLC
$78,362
GlaxoSmithKline, LLC.
$72,917
Horizon Pharma plc
$48,852
Amgen Inc.
$47,791
AbbVie Inc.
$43,897
AstraZeneca Pharmaceuticals LP
$37,572
Janssen Scientific Affairs, LLC
$37,231
Novartis Pharmaceuticals Corporation
$34,932
PFIZER INC.
$31,976
GENZYME CORPORATION
$31,872
Mallinckrodt Enterprises LLC
$20,835
Mallinckrodt LLC
$20,115
Genentech USA, Inc.
$18,345
UCB, Inc.
$11,832
Mallinckrodt Hospital Products Inc.
$11,101
Ironwood Pharmaceuticals, Inc
$9,702
MEDEXUS PHARMA, INC.
$8,791
Pfizer Inc.
$3,700
Regeneron Healthcare Solutions, Inc.
$3,687
E.R. Squibb & Sons, L.L.C.
$2,496
MEDAC PHARMA, INC.
$2,250
Collegium Pharmaceutical, Inc.
$832
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$670
Intra-Sana Laboratories
$437
Boehringer Ingelheim Pharmaceuticals, Inc.
$429
Pacira Pharmaceuticals Incorporated
$345
Aurinia Pharma U.S., Inc.
$342
Hikma Pharmaceuticals USA
$315
Egalet US Inc
$301
Daiichi Sankyo Inc.
$265
DePuy Synthes Sales Inc.
$265
NOVARTIS PHARMACEUTICALS CORPORATION
$258
Phathom Pharmaceuticals, Inc.
$251
SANOFI-AVENTIS U.S. LLC
$219
IDORSIA PHARMACEUTICALS US INC
$199
Bioventus LLC
$192
Takeda Pharmaceuticals U.S.A., Inc.
$183
Kowa Pharmaceuticals America, Inc.
$170
US WorldMeds, LLC
$168
ANI Pharmaceuticals, Inc.
$158
Pernix Therapeutics Holdings, Inc.
$157
Alexion Pharmaceuticals, Inc.
$153
Flexion Therapeutics, Inc.
$143
Zyla Life Sciences
$119
Fresenius Kabi USA, LLC
$110
Sobi, Inc
$99
Organon LLC
$95
Smith+Nephew, Inc.
$94
Genentech, Inc.
$80
Radius Health, Inc.
$73
Cumberland Pharmaceuticals, Inc.
$67
SCILEX PHARMACEUTICALS INC.
$49
Sandoz Inc.
$47
SOBI, INC
$44
Celltrion USA Inc.
$43
Organon Llc
$42
Sebela Pharmaceuticals Inc.
$41
Pacira Therapeutics, Inc.
$41
Eisai Inc.
$38
Bayer Healthcare Pharmaceuticals Inc.
$38
Nevro Corp.
$38
Ferring Pharmaceuticals Inc.
$35
Bayer HealthCare Pharmaceuticals Inc.
$32
Kiniksa Pharmaceuticals, Ltd.
$29
Endo Pharmaceuticals Inc.
$29
Vertical Pharmaceuticals, LLC
$27
West-Ward Pharmaceuticals
$25
TerSera Therapeutics LLC
$25
USWM, LLC
$24
Kaleo, Inc.
$23
SI-BONE, INC.
$23
Shionogi Inc
$23
Assertio Therapeutics, Inc.
$16
ARBOR PHARMACEUTICALS, INC.
$14
Merck Sharp & Dohme Corporation
$14
Sentynl Therapeutics, Inc.
$13
Allergan Inc.
$13
Virtus Pharmaceuticals LLC
$13
Mission Pharmacal Company
$12
Top 3 companies account for 35.8% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ACTIMMUNE · ARYMO ER · Actemra · Adempas · Arcalyst · BENLYSTA · Belbuca · Bimzelx · Binosto · COLOGUARD · COSENTYX · CYLTEZO · Cimzia · DUEXIS · DUZALLO · Dayvigo · Durolane · EUCRISA · EUFLEXXA · EVENITY · EVUSHELD · EVZIO · Enbrel · Evzio · FORTEO · GELSYN 3 · GLYCATE · HADLIMA · HUMIRA · HYRIMOZ · Horizant · Humira · IDACIO · IFUSE IMPLANT · ILARIS · INFLECTRA · Iovera · JOURNEY II CR · KEVZARA · KEVZARA SARILUMAB INJECTION · KINERET · KRYSTEXXA · Kineret · Kloxxado · LEVORPHANOL TARTRATE · LINZESS · LORZONE · LUPKYNIS · LYRICA · Levorphanol · Livalo · Lucemyra · Lucemyra/Lofexidine · METHYLPHENIDATE 72 · MONOVISC · MOVANTIK · Mitigare · Morphabond ER · Motegrity · NASCOBAL · NURTEC ODT · OFEV · OLUMIANT · ORENCIA · ORTHOVISC · OXAYDO · Otezla · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · QMIIZ ODT · QULIPTA · QUVIVIQ · RAYOS · REDITREX · RELISTOR · RELISTOR ORAL · RELTONE 200 MG · RENFLEXIS · REYVOW · RHEUMATOID ARTHRITIS DISEASE · RIDAURA · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SEGLENTIS · SIMPONI · SIMPONI ARIA · SKYRIZI · SPRIX · STELARA · STRENSIQ · SYMJEPI · Seglentis · Senza · Strensiq · Symproic · TALTZ · TAVNEOS · TREMFYA · TREXIMET · TRINTELLIX · Tavneos · Trintellix · Tymlos · UBRELVY · Uloric · VIMOVO · VOQUEZNA · XELJANZ · XTAMPZA · XTAMPZAER · Xtampza ER · YUFLYMA · ZOHYDRO ER · ZORVOLEX · ZTLido · Zilretta · Zipsor
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (96%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in optician and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for optician in NJ.
Geographic Context
Opticians within 10 mi
7,129
Per 100K population
1107.6
County median income
$122,727
Nearest hospital
RIVERVIEW MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Haddad is a mixed practice specialist, with above-average Medicare volume (top 0% in NJ), with speaking/promotional industry engagement in the top 0% of NJ peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Haddad experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Haddad performed 313,200 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Haddad receive payments from pharmaceutical companies?
Yes. Dr. Haddad received a total of $1,184,634 from 84 companies across 3,812 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Haddad's costs compare to other opticians in Red Bank?
Dr. Haddad's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Haddad) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Red Bank
Browse opticians in Red Bank ranked by procedure volume and transparency data.
Highest volume
Top Opticians in NJ
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in NJ
Which NJ opticians receive the most from drug and device companies.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Horizon Therapeutics plc Payments to Doctors
See all physicians who received payments from Horizon Therapeutics plc.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology